Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay022 with Endocrine Therapy in ER+/HER2+ Advanced Breast Cancer
NCT03308201Phase 1Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Oct 2017
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sacibertinib in breast cancer (3 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Number of participants with adverse events. Started Oct 2017; status: completed.
02
Drugs
sacibertinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03308201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308201.